251 related articles for article (PubMed ID: 16277025)
21. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
22. Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
Hildebrandt B; Dräger J; Kerner T; Deja M; Löffel J; Stroszczynski C; Ahlers O; Felix R; Riess H; Wust P
Int J Hyperthermia; 2004 May; 20(3):317-33. PubMed ID: 15204528
[TBL] [Abstract][Full Text] [Related]
23. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
[TBL] [Abstract][Full Text] [Related]
25. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
26. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
27. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
29. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer.
Lissoni P; Rovelli F; Brivio F; Zago R; Colciago M; Messina G; Mora A; Porro G
In Vivo; 2009; 23(1):171-5. PubMed ID: 19368145
[TBL] [Abstract][Full Text] [Related]
30. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
Lissoni P; Mengo S; Bucovec R; Brivio F; Fumagalli L; Tancini G; Gardani GS
In Vivo; 2003; 17(1):73-5. PubMed ID: 12655794
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin in the treatment of colorectal cancer.
Kim GP; Erlichman C
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
[TBL] [Abstract][Full Text] [Related]
33. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
[TBL] [Abstract][Full Text] [Related]
34. [Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
Brivio F; Fumagalli L; Fattori L; Nespoli L; Denova M; Sargenti E; Nespoli A
Minerva Chir; 2004 Dec; 59(6):573-82. PubMed ID: 15876991
[TBL] [Abstract][Full Text] [Related]
35. Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer.
Susak YM; Zemskov VS; Yaremchuk OY; Kravchenco OB; Yatsyk IM; Korsh OB
Drugs Exp Clin Res; 1996; 22(3-5):115-22. PubMed ID: 8899313
[TBL] [Abstract][Full Text] [Related]
36. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Meregalli S; Fossati V; Fumagalli L; Brivio F; Tancini G
Oncology; 1995; 52(3):243-5. PubMed ID: 7715908
[TBL] [Abstract][Full Text] [Related]
37. Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
Bovo G; Brivio F; Brenna A; Fumagalli L; Perego P; Brivio O; Uggeri F; Lavorato F; Bratina G
Pathologica; 1995 Apr; 87(2):135-8. PubMed ID: 8532404
[TBL] [Abstract][Full Text] [Related]
38. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779
[TBL] [Abstract][Full Text] [Related]
39. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
[TBL] [Abstract][Full Text] [Related]
40. Weekly epirubicin plus low-dose interleukin-2 subcutaneous therapy in breast cancer: preliminary immunobiological results.
Lissoni P; Barni S; Ardizzoia A; Fossati V; Paolorossi F; Tancini G
J Biol Regul Homeost Agents; 1994; 8(2):53-5. PubMed ID: 7863813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]